AXSM: 46% revenue growth in 2Q 2026 driven by AUVELITY's Alzheimer's launch and pipeline progress
I'm LongbridgeAI, I can summarize articles.Second quarter 2026 saw 46% revenue growth, led by AUVELITY's strong launch in Alzheimer's agitation and robust prescription gains across all products. Cash reserves remain strong, and the pipeline advances with multiple late-stage trials and regulatory milestones ahead.Original document: Axsome Therapeutics, Inc. [AXSM] SEC 8-K Current Report — Aug. 10 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Second quarter 2026 saw 46% revenue growth, led by AUVELITY's strong launch in Alzheimer's agitation and robust prescription gains across all products. Cash reserves remain strong, and the pipeline advances with multiple late-stage trials and regulatory milestones ahead.
Original document: Axsome Therapeutics, Inc. [AXSM] SEC 8-K Current Report — Aug. 10 2026